Health Care & Life Sciences » Biotechnology | Oncimmune Holdings PLC

Oncimmune Holdings PLC | Balance Sheet

Fiscal year is June-May. All values GBP Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,568.00
1,344.00
10,197.00
5,075.00
12,953
Total Accounts Receivable
830.00
417.00
358.00
241.00
291
Inventories
-
-
188.00
323.00
295
Other Current Assets
18.00
111.00
81.00
20.00
-
Total Current Assets
2,416.00
1,872.00
10,824.00
5,659.00
13,539
Net Property, Plant & Equipment
66.00
48.00
253.00
230.00
201
Intangible Assets
-
30.00
131.00
518.00
671
Total Assets
2,482.00
1,950.00
11,208.00
6,407.00
14,411
ST Debt & Current Portion LT Debt
121.00
562.00
496.00
502.00
Accounts Payable
291.00
200.00
379.00
590.00
Income Tax Payable
-
-
57.00
54.00
Other Current Liabilities
698.00
879.00
150.00
257.00
Total Current Liabilities
1,110.00
1,641.00
1,082.00
1,403.00
Long-Term Debt
3,179.00
4,058.00
395.00
-
Other Liabilities
71.00
71.00
-
-
Total Liabilities
4,360.00
5,770.00
1,477.00
1,403.00
Common Equity (Total)
1,878.00
3,820.00
9,731.00
5,004.00
Total Shareholders' Equity
1,878.00
3,820.00
9,731.00
5,004.00
Total Equity
1,878.00
3,820.00
9,731.00
5,004.00
Liabilities & Shareholders' Equity
2,482.00
1,950.00
11,208.00
6,407.00

About Oncimmune Holdings

View Profile
Address
Clinical Sciences Building
Nottinghamshire Nottingham NG5 1PB
United Kingdom
Employees -
Website http://www.oncimmune.com
Updated 07/08/2019
Oncimmune Holdings Plc is an early cancer detection company that engages in the development and commercialization of its proprietary EarlyCDT platform technology. It has pioneer the development of tests based on the presence in the blood of autoantibody against specific tumor associated antigens that have the potential to detect cancer up to four years earlier than other methods of cancer detection, such as a chest X-ray, Spiral Computed Tomography or emerging technologies that do not benefit from the amplification of signal that occurs with the immune system, and can be applied to a very wide range of solid tumor types. The company was founded on October 9, 2015 and is headquartered in Nottinghamshire, the United Kingdom.